biostudies-literatureDelles COulun YliopistoNovo Nordisk FoundationThe Engineering and Physical Sciences Research CouncilUniversity of BristolSigrid Juselius FoundationEuropean Commission under the Health Cooperation Work Programme of the 7th Framework ProgrammeAcademy of FinlandEuropean Federation of Pharmaceutical Industries Associations (EFPIA)The Medical Research CouncilEuropean Medical Information Framework (EMIF)Medical Research CouncilFinnish FoundationInnovative Medicines Initiative Joint UndertakingNovo Nordisk Fonden663-673https://www.ebi.ac.uk/biostudies/studies/S-EPMC5947152biostudies-literatureUnknown20(4)<h4>Aims</h4>We investigated the association between quantified metabolite, lipid and lipoprotein measures and incident heart failure hospitalisation (HFH) in the elderly, and examined whether circulating metabolic measures improve HFH prediction.<h4>Methods and results</h4>Overall, 80 metabolic measures from the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) trial were measured by proton nuclear magnetic resonance spectroscopy (n = 5341; 182 HFH events during 2.7-year follow-up). We repeated the work in FINRISK 1997 (n = 7330; 133 HFH events during 5-year follow-up). In PROSPER, the circulating concentrations of 13 metabolic measures were found to be significantly different in those who were later hospitalised for heart failure after correction for multiple comparisons.European journal of heart failureNuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation: results from PROSPER and FINRISK 1997.PMC5947152305507115372MC_UU_1201/1294834MR/N005813/1NNF15OC0015998Delles CFord IKangas ABoachie CJukema JWZannad FSalomaa VWurtz PSattar NMcConnachie ARankin NJSoininen PMooijaart SPAla-Korpela MHavulinna ASWelsh PTrompet SfalseNuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation: results from PROSPER and FINRISK 1997.<h4>Aims</h4>We investigated the association between quantified metabolite, lipid and lipoprotein measures and incident heart failure hospitalisation (HFH) in the elderly, and examined whether circulating metabolic measures improve HFH prediction.<h4>Methods and results</h4>Overall, 80 metabolic measures from the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) trial were measured by proton nuclear magnetic resonance spectroscopy (n = 5341; 182 HFH events during 2.7-year follow-up). We repeated the work in FINRISK 1997 (n = 7330; 133 HFH events during 5-year follow-up). In PROSPER, the circulating concentrations of 13 metabolic measures were found to be significantly different in those who were later hospitalised for heart failure after correction for multiple comparisons.2018-01-01T00:00:00Z2018 Apr2025-04-04T19:25:51.788Z2019-03-26T23:37:44ZS-EPMC59471522922661010.1002/ejhf.1076